Pharmaceutical Executive, May 1, 2013 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, May 1, 2013
Features
Tracking Trial Cost Drivers: The Impact of Comparator Drugs and Co-Therapies
By Mary Jo Lamberti , Ken Getz
New research from the Tufts Center for the Study of Drug Development identifies a significant contributor to the rising cost of clinical trials—the first step in meeting a growing strategic imperative to help senior management and the regulatory community craft new approaches to make trials more efficient in delivering results to clinicians and patients.
2013 Pharm Exec Top 50
By Waseem Noor
Patent expiries dampen revenues for some of the biggest Big Pharma, but growth continues unabated for a few nimble "stealth" players moving steadily up the list.
The Friendly Persuasion — An Interview with Fred Hassan
By William Looney
What is industry icon Fred Hassan's management formula for staying fresh in an era of market churn?
Country Report
Country Report: Austria
While Austria experienced significant political and economic shake-up throughout the 20th century, the country has remained a key strategic market for the pharmaceutical industry thanks to its steady economic development and inclination for innovation.
Column
Is That VBP on the Horizon, or a Mirage?
By Julian Upton
Value-based pricing in the United Kingdom is getting closer, but it remains out of focus.
The Big Squeeze
New approaches to managing reimbursements for pharmacy benefit programs are testing Big Pharma.
It's Time For a Code of Ethics in Patient Education
In the world of patient education, processes, policies, and oversight differ vastly. There is no overarching governance structure. There isn't an accreditation process for educational interventions or patient advocacy organizations that develop the education.
The New Commercial Model Myth
By Stan Bernard, MD
Pharma professionals need to find new competitive—not commercial—models to succeed in the competitive stage of the industry's lifecycle, writes Stan Bernard.
Obamacare Will Boost Private Managed Care
Public access expansion under the ACA isn't really a "government takeover."
The Health Information Advantage
For the hard-pressed oncology practice, new technologies hold the key to surviving—and thriving.
Whistling Past the Graveyard
By Ben Comer
A night of comedy in support of a chronic disease.
Generic Drug Gains and Grumbles
By Jill Wechsler
Legal battles and regulatory missteps undermine access to low-cost generics, at home and abroad, writes Jill Wechsler.
From the Editor
The Patent Black Label
By William Looney
Last month's decision by India's Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve—but the implications in and beyond India are both immediate and lasting.

ADVERTISEMENT

Click here